These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16436779)

  • 1. Cabergoline and mitral regurgitation.
    Delgrange E
    N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
    Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
    Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline-related severe restrictive mitral regurgitation.
    Pinero A; Marcos-Alberca P; Fortes J
    N Engl J Med; 2005 Nov; 353(18):1976-7. PubMed ID: 16267335
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
    Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
    Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
    Cawood TJ; Bridgman P; Hunter L; Cole D
    Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine agonists and valvular heart disease.
    Stephens JW; Price DE; Ionescu A
    N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17442913
    [No Abstract]   [Full Text] [Related]  

  • 8. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
    Sherlock M; Toogood AA; Steeds R
    Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
    Lökk J
    Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mitral valve replacement for cabergoline-related severe mitral regurgitation].
    Hanada T; Shimizu K; Murakami R; Ota T; Okada S; Inoue S; Hiroe K; Higaki Y; Oda T
    Kyobu Geka; 2007 Oct; 60(11):1018-21. PubMed ID: 17926907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
    Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
    [No Abstract]   [Full Text] [Related]  

  • 13. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
    Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline and the risk of valvular lesions in endocrine disease.
    Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
    Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study.
    Ozer N; Yorgun H; Canpolat U; Elibol B
    Anadolu Kardiyol Derg; 2014 Mar; 14(2):121-7. PubMed ID: 24449623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiopulmonary complications of ergot-derivative dopamine agonists.
    Rack MJ; Baran AS; Richert AC; Roffwarg HP
    J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of iatrogenic severe mitral regurgitation.
    D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
    Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
    Samson SL; Ezzat S
    Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
    Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency of cardiac valvular regurgitation in Parkinson's disease.
    Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
    Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.